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Abstract 
Aim To compare disease severity and clinical outcome of Clostridium difficile 
infection (CDI) due to PCR-ribotype (RT) 244 with CDI due to other strains present 
in Auckland.  
Method A retrospective, case-control study was conducted. Ten cases with CDI due 
to RT 244 were compared with 20 controls infected with other C. difficile strains. RT 
244 isolates were further analysed for antimicrobial susceptibility, binary toxin genes 
and mutations in the tcdC gene. 
Results Cases were significantly more likely to have severe disease than controls (OR 
9.33; p=0.015). 50% of cases had community-associated CDI compared with 15% of 
controls (p=0.078). All RT 244 isolates produced binary toxin and had a single-base 
pair deletion in tcdC at position 117. 
Conclusion C. difficile RT 244 is a newly recognised strain in New Zealand. It shares 
several features that characterise RT 027. Given its propensity to cause severe 
community-associated disease, a heightened awareness of this strain is needed to 
ensure early testing in patients admitted from the community with identified risk 
factors for CDI.  
Clostridium difficile infection (CDI) is the commonest cause of healthcare-associated 
diarrhoea. In Europe and North America the incidence and severity of Clostridium 
difficile infection (CDI) has increased over the past decade.
1
 This increase has been 
attributed largely to the emergence of so called “hypervirulent” strains such as PCR-
ribotype (RT) 027.
2




Recently a cluster of “presumptive 027” cases was identified in Melbourne, Australia 
(personal communication, Dr R. Stuart, Monash Medical Centre, 2012). On further 
testing the isolates were not confirmed as RT 027 but rather a ribotype new to 
Australia designated RT 244. Preliminary investigations showed that compared to 
other strains, infection with RT 244 was associated with severe community-onset 
disease and higher mortality. In New Zealand a newly recognised strain of C. difficile, 
identified during a national survey in November 2011 was compared to RT 244 and 
the ribotyping patterns were indistinguishable.  
We sought to compare disease severity and clinical outcome of CDI due to RT 244 
with CDI due to other C. difficile strains circulating during the same time period. We 
further characterised RT 244 by performing antimicrobial susceptibility testing 
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against moxifloxacin, clindamycin and metronidazole, and determining the presence 
of the binary toxin genes and mutations in the tcdC gene. 
Methods 
A retrospective, matched case-control study was undertaken. The cases were 10 patients with CDI due 
to RT 244 who were hospitalised in the Auckland region of New Zealand between October 2011 and 
May 2012. Each case was matched for age (±10 years) and gender with two controls. Controls were 
drawn from patients within the Auckland region who had C. difficile other than RT 244 isolated from 
stool.  
Data collected included: demographics; comorbidities; hospitalisation in the preceding 6 months; 
location at symptom onset; antibiotic exposure during 4 weeks prior to symptom onset; and exposure to 
H2 antagonists, proton-pump inhibitors or chemotherapy. For each patient, the Charlson Co-morbidity 
Index was calculated.
5
 Disease severity, treatment regimen, disease recurrence and all-cause 30-day 
mortality were also determined. 
CDI was defined as the presence of diarrhoea and a positive stool C. difficile toxin result. Each patient 
was classified as having either community or healthcare-associated disease using surveillance 
definitions.
6
 Community-associated (CA-CDI) was defined as CDI symptom onset in the community, 
or within 48 hours after admission to a healthcare facility, provided symptom onset was more than 12 
weeks after the last discharge from a healthcare facility.  
Severe CDI was defined as an episode of CDI with one or more signs of severe colitis including: fever 
(temperature >38.5 °C); rigors; haemodynamic instability; signs of ileus; marked leukocytosis 
(leukocyte count >15 × 10
9
 × /L); marked left shift (band neutrophils >20% of leukocytes); rise in 
creatinine (>50% above baseline); pseudomembranous colitis and abnormal imaging including 
distension of large intestine; colonic wall thickening including low-attenuation mural thickening; 
pericolonic fat stranding; and ascites not explained by other causes.
7
 These markers could not be 
attributable to a concomitant disease.  
CDI recurrence was considered to have occurred if there was reappearance of symptoms after initial 
improvement, or if there was a further positive toxin result within 8 weeks of the last positive toxin 
result in combination with a prescription for metronidazole. 
Stool specimens were inoculated onto chromogenic C. difficile agar (ChromID
TM
 C. difficile, 
BioMérieux, Marcy L’Etoile, France) and colonies with typical appearance were identified by routine 
laboratory methods. PCR-ribotyping was performed by a standard method using capillary-gel 
electrophoresis.
8
 PCR for binary toxin genes and tcdC gene sequencing for detection of tcdC gene 
mutations was performed as previously described.
9,10
  
Antimicrobial susceptibility testing of the RT 244 isolates was performed using metronidazole 
M.I.C.E. strips (Oxoid, Thermo Fisher Scientific Inc, Hampshire, United Kingdom) and moxifloxacin, 
clindamycin and vancomycin Etests (BioMerieux, Marcy L’Etoile, France).  
The study was assessed by the Northern Region Ethics Committee and formal approval was not 
considered necessary. 
Statistical analysis—Continuous and categorical variables were compared using the Student t test and 
Fisher exact test, respectively. P<0.05 was considered significant. 
Results 
Compared with controls, cases with RT 244 causing CDI were significantly more 
likely to have severe disease (OR 9.33; 95% confidence interval 1.27-82.59; 
p=0.015). In addition, 50% of cases had CA-CDI compared with 15% of controls, 
although this difference was not significant (p=0.078). There were no significant 
differences between the cases and controls in comorbidities, antibiotic exposure in the 
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Table 1. Comparison of cases with Clostridium difficile PCR-ribotype 244 
infection and controls infected with other C. difficile strains 
 






OR (95% CI) P value 
Mean CCI 3.5 5.45  0.095 
Risk factors     
Antibiotic therapy
b
 7 (70%) 19 (95%) 0.123 (0.004–1.76) 0.095 
PPI/H2 antagonist 5(50%) 16 (80%) 0.25 (0.03–1.70) 0.115 
Chemotherapy 0 1 (5%) – 1.000 
CA-CDI 5(50%) 3 (15%) 5.67 (0.76–48.23) 0.078 
Outcome     
Severe disease 7 (70%) 4 (20%) 9.33 (1.27–82.59) 0.015 
Recurrence 4 (40%) 3 (15%) 3.78 (0.49–31.85) 0.181 
30-day all-cause mortality 1 (10%) 3 (15%) 0.63 (0.02–8.9) 1.000 
Abbreviations: OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; PPI, proton-pump 
inhibitor; CA-CDI, community-associated C. difficile infection. 
a PCR-ribotypes among controls included 002 (3), 014 (5), 020 (1), 070 (3), NZ 11/12 (1), NZ 11/14 (1), NZ 11/16 
(1), NZ 11/17 (2), NZ 11/24 (1), NZ 11/25 (1) and NZ 11/30 (1). (Strains that did not match the European Centre 
for Disease Prevention and Control’s set of reference strains were assigned New Zealand PCR-ribotype strain 
number prefixed with ‘NZ11/’). 
b Antibiotic therapy in 4 weeks prior to symptom onset. 
 
The three cases that underwent endoscopy all had macroscopic evidence of 
pseudomembranous colitis. In comparison, the only control patient that underwent 
endoscopy did not have macroscopic evidence of pseudomembranous colitis although 
histological evidence of pseudomembranous colitis was apparent following colectomy 
for toxic megacolon.  
All 10 C. difficile RT 244 isolates were susceptible to moxifloxacin (minimum 
inhibitory concentration (MIC) 1 mg/L) and metronidazole (MIC 0.25-0.5 mg/L) by 
CLSI criteria.
11
 The clindamycin MICs ranged from 2 to 4 mg/L (the breakpoint for 
resistance is ≥8 mg/L). All isolates were susceptible to vancomycin (MIC 1 mg/L) by 
EUCAST criteria.
12
 All 10 isolates carried the binary toxin genes and had a 1-base 
pair deletion in the tcdC regulatory gene at position 117. No additional deletions or 
insertions were found within the tcdC gene. 
Discussion  
This study reports on the characteristics of C. difficile infection caused by RT 244 
strains. This is a newly recognised strain in New Zealand. In our study, patients 
infected with RT 244 were more likely to present with severe disease (p=0.015) and 
there was a trend towards community-associated disease (p=0.078) similar to the 
findings in the Australian cohort.  
Traditionally, CDI has been considered a hospital-acquired infection and testing of 
patients presenting with community-onset diarrhoea for CDI is not standard practice 
in New Zealand. These findings provide further support to suggestions that CDI 
should be considered in the differential diagnosis of adult patients presenting with 
community-onset diarrhoea, in whom routine enteric pathogens have been excluded 
and, in particular, for patients with severe diarrhoea and who have had a recent course 
of antibiotics.  
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This strain has features similar to C. difficile RT 027, in particular, the presence of 
binary toxin and a 1-base pair deletion at position 117 in the tcdC gene. Indeed, whole 
genome sequencing undertaken at Oxford University suggests that these two strains 
have descended from a common ancestor (Prof TV Riley et al., unpublished data, 
2012). However, RT 244 lacks the 18-base pair tcdC deletion characteristic of RT 
027. Another major difference between the recent epidemic RT 027 and RT 244 is 
susceptibility to moxifloxacin; epidemic RT 027 isolates are typically resistant 
whereas RT 244 isolates are susceptible. 
Testing algorithms for CDI differ between hospitals in New Zealand.
13
 Laboratories 
that use the GeneXpert C. difficile PCR assay are likely to detect RT 244 as the assay 
offers presumptive identification of RT 027 based on the presence of binary toxin 
genes and a 1-base pair deletion in the tcdC gene at position 117. However, most 
testing algorithms limit the use of the GeneXpert assay to testing of samples that have 
glutamate dehydrogenase, but not toxin, detected by an enzyme immunoassay. With 
this algorithm, infections caused by the RT 244 strain may go undetected, unless other 
circumstances, such as severe disease, trigger further testing.  
This study has a number of limitations. It was retrospective and the quality of 
documentation in the clinical records was variable. There were only 10 cases and this 
may have limited our ability to show statistical difference between the cases and the 
controls. Regardless, our findings highlight the need for an increased awareness of C. 
difficile RT 244 and its potential risks, given its similarity to RT 027, and support 
calls for enhanced measures for its diagnosis in our patient population. 
The source of this newly emerging strain is not known. It belongs to the same clonal 
lineage as RT 027 and has the potential to cause severe disease with significant 
morbidity and mortality in patients with and without comorbidities.
14,15 
Severe disease 
can be defined in a number of ways.  
A recent study in which severe disease was defined as intensive care admission, 
interventional surgery or death within 30 days of diagnosis, failed to show an 
association between specific ribotypes and severe infection.
16 
White cell count and 
albumin level at presentation were the most clinically relevant predictors of severe 
disease in that study.  
We used a definition for severe disease based on clinical and laboratory findings 
which may explain the association between infection with RT 244 and disease 
severity. Also, there was a trend towards community-associated disease suggesting 
that our patients were less likely to have some of the risk factors traditionally 
associated with CDI. 
Further work needs to be done to determine the reservoirs of this strain. It is important 
that we focus on infection prevention and control measures that should reduce the 
introduction and transmission of this strain at least in healthcare settings.  
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